Advertisement
Advertisement
NRIX
Nurix Therapeutics, Inc. Common stock
23.01
USDSponsored
-0.64
-2.71%
Sep 25, 15:59 UTC -4
Closed
After-Market
23.00
-0.01
-0.02%
NRIX Earnings Reports
Positive Surprise Ratio
NRIX beat 10 of 24 last estimates.
42%
Next Report
Date of Next Report
Oct 07, 2026
Estimate for Q3 26 (Revenue/ EPS)
$24.77M
/-$0.61
Implied change from Q2 26 (Revenue/ EPS)
+173.89%
/-24.69%
Implied change from Q3 25 (Revenue/ EPS)
+213.76%
/-40.78%
Nurix Therapeutics, Inc. Common stock earnings per share and revenue
On Jul 09, 2026, NRIX reported earnings of -0.81 USD per share (EPS) for Q2 26, missing the estimate of -0.73 USD, resulting in a -10.78% surprise. Revenue reached 9.04 million, compared to an expected 16.49 million, with a -45.17% difference. The market reacted with a -6.60% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.61 USD, with revenue projected to reach 24.77 million USD, implying an decrease of -24.69% EPS, and increase of 173.89% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Nurix Therapeutics, Inc. Common stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Nurix Therapeutics, Inc. Common stock reported EPS of -$0.81, missing estimates by -10.78%, and revenue of $9.04M, -45.17% below expectations.
How did the market react to Nurix Therapeutics, Inc. Common stock's Q2 2026 earnings?
The stock price moved down -6.6%, changed from $24.69 before the earnings release to $23.06 the day after.
When is Nurix Therapeutics, Inc. Common stock expected to report next?
The next earning report is scheduled for Oct 07, 2026.
What are the forecasts for Nurix Therapeutics, Inc. Common stock's next earnings report?
Based on 10
analysts, Nurix Therapeutics, Inc. Common stock is expected to report EPS of -$0.61 and revenue of $24.77M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.